ScreenerHero

PRTC PureTech Health plc

LSE · GB · Healthcare · Biotechnology · puretechhealth.com
107.60GBp-0.19%Mkt Cap: 284.69M $P/E: —

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap284.69M USD
Enterprise Value268.34M USD
Revenue (TTM)6.92M USD
Gross Profit-64.20M USD
Net Income (TTM)-119.28M USD
Revenue/Share0.03 GBp
Last Price107.60 GBp
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees90
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.56
PEG—
EV/EBITDA-2.44
EV/Revenue38.79
P/S41.23
P/B0.90
EPS (TTM)0.00
EPS (Forward)-0.30
52W Range
106.772% of range143.60
52W High143.60 GBp
52W Low106.77 GBp
Profitability
Gross Margin0.00%
Oper. Margin-1470.37%
EBITDA Margin0.00%
Profit Margin-2355.42%
ROE-35.16%
ROA-20.52%
Growth
Revenue Growth92.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-92.53M USD
CapEx (TTM)6.52K USD
FCF Margin-1481.68%
FCF Yield-36.01%
Net Debt-9.56M USD
Net Debt/EBITDA0.09
Balance Sheet
Debt/Equity0.06
Current Ratio4.60
Quick Ratio4.38
Book Value/Sh1.20 GBp
Cash/Share0.95 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 GBp
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)370.29 GBp
Upside (mean)+244.1%
Target Range247.89 GBp – 509.50 GBp
247.89+244.1% to mean509.50
# Analysts3
Ownership
Shares Out.243.42M
Float157.42M
Insiders10.00%
Institutions52.38%
Technical
SMA 50119.01 (-9.6%)
SMA 200124.99 (-13.9%)
Beta0.78
S&P 52W Chg14.58%
Avg Vol (30d)756.45K
Avg Vol (10d)808.67K
Technical Indicators
RSI (14)33.5
MACD-2.5034
MACD Signal-1.5073
MACD Hist.-0.9961
BB Upper126.14 GBp
BB Middle117.57 GBp
BB Lower109.00 GBp
BB Width14.57%
ATR (14)5.076 GBp
Vol Ratio (20d)1.27x